KLK1 and systemic lupus erythematosus: Our study interestingly revealed that tissue Klk1 can effectively inhibit the key signaling molecules in the Type I IFN pathway, suggesting that this is a potential candidate to develop as a biologic not only for lupus but for other IFN-mediated diseases.